Department of Oral and Maxillofacial Surgery, Royal Perth Hospital, Perth, Western Australia, Australia.
ANZ J Surg. 2023 Apr;93(4):869-875. doi: 10.1111/ans.18186. Epub 2022 Dec 14.
Diffuse type tenosynovial giant cell tumour of the temporomandibular joint (D-TGCT-TMJ) is a rare proliferative disorder. The aim of this study was to perform a systematic review of the literature to summarize D-TGCT-TMJ management regimes and recurrence rates with at least 12 months of follow-up. Our secondary aim was to propose a minimum period of post-operative follow-up. A medline search for any D-TGCT-TMJ case detailing treatment, follow-up of at least 12 months, and presence of recurrence was undertaken. The following variables were extracted from the studies: patient's age and sex, presence of middle cranial fossa invasion, treatment undertaken, total length of follow-up, and presence of recurrence. All studies were assessed for bias as per the Joanna Briggs Institute systematic reviews appraisal tool. There were 63 cases reviewed and were predominantly managed with total resection (60.3%). Other modalities included: arthroplasty, subtotal resection with or without postoperative radiotherapy, medical therapy and surveillance. The recurrence rate was 9.52% and the longest follow-up period where recurrence was observed was at 60 months. Total resection and arthroplasty are common D-TGCT-TMJ management regimes. Patients with D-TGCT-TMJ should be followed up annually for at least 5 years postoperatively to assess for recurrence.
弥漫型颞下颌关节腱鞘巨细胞瘤（D-TGCT-TMJ）是一种罕见的增殖性疾病。本研究旨在对文献进行系统回顾，总结至少 12 个月随访的 D-TGCT-TMJ 治疗方案和复发率。我们的次要目的是提出术后随访的最短时间。对详细描述治疗、随访至少 12 个月且存在复发的任何 D-TGCT-TMJ 病例进行了 medline 检索。从研究中提取了以下变量：患者的年龄和性别、是否存在中颅窝侵犯、所进行的治疗、总随访时间以及是否存在复发。根据 Joanna Briggs 研究所系统评价工具评估了所有研究的偏倚。共回顾了 63 例病例，主要采用全切除术（60.3%）治疗。其他治疗方式包括：关节成形术、全切除术后部分切除加或不加术后放疗、药物治疗和监测。复发率为 9.52%，观察到复发的最长随访时间为 60 个月。全切除术和关节成形术是常见的 D-TGCT-TMJ 治疗方案。D-TGCT-TMJ 患者应在术后至少 5 年内每年进行随访，以评估复发情况。
